Newsletter May 2024

ONO Pharma USA Announces 2024 Golden Ticket Competition

Applications are now open for the ONO Pharma Golden Ticket Competition, awarding two promising early-stage R&D companies lab space and mentorship. The competition seeks proposals from therapeutics companies working in oncology, immunology, neurology, and other indication areas with high unmet medical needs.

We are proud to partner with ALIT!

ALIT LifeTech provides advanced instruments, high-quality reagents and consumables, and dependable services to the life science and biotherapeutic industry. This partnership brings industry-leading Countstar cell analyzers and the new Castor automated 2D and 3D organoid high content imaging system to our core at our 953 Indiana St, San Francisco campus.

Thank you to ALIT for your support of our community’s scientists in advancing life science research and developing next generation therapeutics!

► READ MORE

Unlocking Longevity with Agilent: Strategies to Extend Your Funding Runway

Learn about the venture funding environment and how you can extend your runway through creative capital equipment financing options, including a month-to-month subscription or rental through Agilent. Join us for a dynamic Lunch & Learn hosted by Agilent in partnership with Mission Bay Capital.

May 1 @ noon - 1pm
930 Brittan Ave, San Carlos

May 2 @ noon - 1pm
135 Mississippi St, San Francisco

Li-Cor Lunch & Learn: Western Blot Best Practices

Please join Niyati Patel from LiCor Bio for a Lunch & Learn seminar on topics including detection chemistry optimization, Western Blot best practices, assay development tools, and image acquisition and data analysis.

May 9 @ noon - 1pm
953 Indiana St, San Francisco

Founders at Work: Montara Therapeutics

Our upcoming Founders at Work Speaker Series features Nick Hertz and Kevan Shokat from Montara Therapeutics - creating innovative therapies for diseases of the CNS, with a focus on precision medicine and genetically validated targets to enhance drug safety and efficacy. This is Nick and Kevan's second company, after building Mitokinin, which was acquired by Abbvie in 2023.

May 9 @ 4pm - 5pm
135 Mississippi St, San Francisco

Lunch & Learn: Navigating the Cell and Gene Therapy Space with Bio-Rad

Please join our partners at Bio-Rad for a Lunch & Learn on the latest information regarding Bio-Rad’s instruments, reagents, and analysis solutions for your cell and gene therapy programs. Take advantage of this opportunity to ask Bio-Rad’s field application scientists your technical questions.

May 21 @ 12pm - 2pm
135 Mississippi St, San Francisco

MBC BioLabs Life Science Vendor’s Showcase May 2024

May 22 @ 10am - 2pm
930 Brittan Ave, San Carlos

The showcase aims to bring together the latest and greatest in life science technologies and services from a variety of vendors. This is an opportunity for our resident scientists and entrepreneurs to explore cutting-edge tools and services, learn about new techniques, resources, and network with other members of the life science community.

Malvern Lunch & Learn

May 29 @ noon - 1pm
135 Mississippi St, San Francisco

Please join our partners at Malvern for a crash course on Dynamic Light Scattering uses in biopharmaceutical development. DLS plays a pivotal role in characterizing size, aggregation, and stability (structural and colloidal).

Partner Office Hours

Connect with our partners from Malvern Panalytical, Agilent, Revvity, or Thermo Fisher Scientific during their scheduled office hours this month!

Integrated Biosciences Partners with Project 8p Foundation to Pioneer a New Path to Groundbreaking Treatments for Chromosomal Disorders

RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment

Multiply Labs Announces Upcoming Collaboration with Stanford Medicine’s Laboratory for Cell and Gene Medicine (LCGM) to Deploy Automated Systems For Cell Therapy Manufacturing

Vertility Health

Vertility Health is tapping into the genetic power of sperm to transform fertility treatments, developing techniques to isolate sperm based on their genetic characteristics and offering a powerful alternative to in vitro fertilization for conception. Vertility’s approach provides a more accessible solution for couples seeking to prevent the transmission of certain genetic conditions to their children. Currently, Vertility’s R&D is focused on using bovine (bull) spermatozoa to refine and improve their technology.

We warmly welcome founder and CEO, Bonnie Maven, to the 930 Brittan community in San Carlos!